{
    "xml": "<topic id=\"PHP5546\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/sunitinib\" basename=\"sunitinib\" title=\"SUNITINIB\">\n<title>SUNITINIB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1075\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/sunitinib\">Sunitinib</xref>\n</p>\n<data name=\"vtmid\">421448007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_208007314\" title=\"Protein kinase inhibitors\">Protein kinase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP39437\" outputclass=\"drugAction\" rev=\"1.9\" parent=\"/drugs/sunitinib\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Sunitinib is a tyrosine kinase inhibitor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39414\" outputclass=\"indicationsAndDose\" rev=\"1.27\" parent=\"/drugs/sunitinib\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours, after failure of imatinib</p>\n<p outputclass=\"therapeuticIndication\">Treatment of advanced or metastatic renal cell carcinoma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5&#8239;mg, doses adjusted according to tolerability; usual dose 25&#8211;75&#8239;mg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of unresectable or metastatic pancreatic neuroendocrine tumours</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>37.5&#8239;mg once daily without treatment-free period; adjusted in steps of 12.5&#8239;mg, doses adjusted according to tolerability; maximum 50&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39444\" outputclass=\"importantSafetyInformation\" rev=\"1.13\" parent=\"/drugs/sunitinib\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risk of osteonecrosis of the jaw (January 2011)</p>\n<p>Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p>\n<p>Patients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p>\n<p>Dental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.</p>\n<p>If possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39461\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/sunitinib\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cardiovascular disease&#8212;discontinue if congestive heart failure develops</ph>; <ph outputclass=\"caution\">hypertension</ph>; <ph outputclass=\"caution\">increased risk of bleeding</ph>; <ph outputclass=\"caution\">susceptibility to QT-interval prolongation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39409\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/sunitinib\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (sunitinib).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39386\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/sunitinib\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Nephrotic syndrome</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">dehydration</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">fistula formation (interrupt treatment if occurs)</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal perforation</ph>; <ph outputclass=\"sideEffect\">hair discoloration</ph>; <ph outputclass=\"sideEffect\">hand-foot syndrome</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">hypothyroidism</ph>; <ph outputclass=\"sideEffect\">increased lacrimation</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">osteonecrosis of the jaw</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">proteinuria</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">seizures</ph>; <ph outputclass=\"sideEffect\">skin discoloration</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">urine discoloration</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39456\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/sunitinib\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;effective contraception required during treatment.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39405\" outputclass=\"pregnancy\" parent=\"/drugs/sunitinib\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39467\" outputclass=\"breastFeeding\" parent=\"/drugs/sunitinib\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39369\" outputclass=\"monitoringRequirements\" parent=\"/drugs/sunitinib\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for thyroid dysfunction.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39355\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/sunitinib\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA169</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Sunitinib for advanced or metastatic renal cell carcinoma (March 2009)</p>\r\n<p>Sunitinib is recommended as first-line treatment for advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA169\">www.nice.org.uk/TA169</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA178</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009)</p>\r\n<p>Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA178\">www.nice.org.uk/TA178</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA179</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Sunitinib for the treatment of gastrointestinal stromal tumours (September 2009)</p>\r\n<p>Sunitinib is recommended as an option for treatment in patients with unresectable or metastatic gastrointestinal tumours if imatinib treatment has failed because of resistance or intolerance, and the cost of sunitinib for the first treatment cycle is met by the manufacturer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA179\">www.nice.org.uk/TA179</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (October 2009 and April 2011) that sunitinib (<i>Sutent</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours after failure of imatinib and for unresectable or metastatic pancreatic neuroendocrine tumours.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5546-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/sunitinib\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75566\" title=\"Capsule\" namespace=\"/drugs/sunitinib/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1075\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/protein-kinase-inhibitors/sunitinib\" title=\"Sunitinib\" count=\"1\" rel=\"link\">Sunitinib</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75566\" namespace=\"/drugs/sunitinib/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP5546",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/sunitinib",
    "basename": "sunitinib",
    "title": "SUNITINIB",
    "interactants": [
        {
            "id": "bnf_int_1075",
            "label": "Sunitinib"
        }
    ],
    "vtmid": "421448007",
    "drugClassification": [
        "Protein kinase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Sunitinib is a tyrosine kinase inhibitor.",
                "html": "<p>Sunitinib is a tyrosine kinase inhibitor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours, after failure of imatinib",
                        "html": "Treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours, after failure of imatinib"
                    },
                    {
                        "textContent": "Treatment of advanced or metastatic renal cell carcinoma",
                        "html": "Treatment of advanced or metastatic renal cell carcinoma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "50 mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5 mg, doses adjusted according to tolerability; usual dose 25&#8211;75 mg daily.",
                        "html": "<p>50&#8239;mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5&#8239;mg, doses adjusted according to tolerability; usual dose 25&#8211;75&#8239;mg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of unresectable or metastatic pancreatic neuroendocrine tumours",
                        "html": "Treatment of unresectable or metastatic pancreatic neuroendocrine tumours"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability; maximum 50 mg per day.",
                        "html": "<p>37.5&#8239;mg once daily without treatment-free period; adjusted in steps of 12.5&#8239;mg, doses adjusted according to tolerability; maximum 50&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risk of osteonecrosis of the jaw (January 2011)",
                "textContent": "Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.\n\nPatients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.\n\nDental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.\n\nIf possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.",
                "html": "<p>Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p><p>Patients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p><p>Dental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.</p><p>If possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p>"
            },
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cardiovascular disease&#8212;discontinue if congestive heart failure develops",
                "html": "Cardiovascular disease&#8212;discontinue if congestive heart failure develops"
            },
            {
                "type": "cautions",
                "textContent": "hypertension",
                "html": "hypertension"
            },
            {
                "type": "cautions",
                "textContent": "increased risk of bleeding",
                "html": "increased risk of bleeding"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to QT-interval prolongation",
                "html": "susceptibility to QT-interval prolongation"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (sunitinib).",
                "html": "<p>Appendix 1 (sunitinib).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Nephrotic syndrome",
                        "html": "Nephrotic syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dehydration",
                        "html": "dehydration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fistula formation (interrupt treatment if occurs)",
                        "html": "fistula formation (interrupt treatment if occurs)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal perforation",
                        "html": "gastro-intestinal perforation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hair discoloration",
                        "html": "hair discoloration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hand-foot syndrome",
                        "html": "hand-foot syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypothyroidism",
                        "html": "hypothyroidism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "increased lacrimation",
                        "html": "increased lacrimation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "osteonecrosis of the jaw",
                        "html": "osteonecrosis of the jaw",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "proteinuria",
                        "html": "proteinuria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "seizures",
                        "html": "seizures",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "skin discoloration",
                        "html": "skin discoloration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urine discoloration",
                        "html": "urine discoloration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;effective contraception required during treatment.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;effective contraception required during treatment.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in animal studies.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for thyroid dysfunction.",
                "html": "<p>Monitor for thyroid dysfunction.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA169",
                        "label": "www.nice.org.uk/TA169"
                    }
                ],
                "fundingIdentifier": "NICE TA169",
                "textContent": "Sunitinib for advanced or metastatic renal cell carcinoma (March 2009) Sunitinib is recommended as first-line treatment for advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1.\n\nwww.nice.org.uk/TA169",
                "html": "<p outputclass=\"title\">Sunitinib for advanced or metastatic renal cell carcinoma (March 2009)</p> <p>Sunitinib is recommended as first-line treatment for advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA169\">www.nice.org.uk/TA169</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA178",
                        "label": "www.nice.org.uk/TA178"
                    }
                ],
                "fundingIdentifier": "NICE TA178",
                "textContent": "Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.\n\nwww.nice.org.uk/TA178",
                "html": "<p outputclass=\"title\">Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009)</p> <p>Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA178\">www.nice.org.uk/TA178</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA179",
                        "label": "www.nice.org.uk/TA179"
                    }
                ],
                "fundingIdentifier": "NICE TA179",
                "textContent": "Sunitinib for the treatment of gastrointestinal stromal tumours (September 2009) Sunitinib is recommended as an option for treatment in patients with unresectable or metastatic gastrointestinal tumours if imatinib treatment has failed because of resistance or intolerance, and the cost of sunitinib for the first treatment cycle is met by the manufacturer.\n\nwww.nice.org.uk/TA179",
                "html": "<p outputclass=\"title\">Sunitinib for the treatment of gastrointestinal stromal tumours (September 2009)</p> <p>Sunitinib is recommended as an option for treatment in patients with unresectable or metastatic gastrointestinal tumours if imatinib treatment has failed because of resistance or intolerance, and the cost of sunitinib for the first treatment cycle is met by the manufacturer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA179\">www.nice.org.uk/TA179</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75566",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1075",
                "label": "Sunitinib",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75566",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}